{'fraction_non_alphanumeric': 0.02505446623093682, 'fraction_numerical': 0.013071895424836602, 'mean_word_length': 4.891025641025641, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Nelfinavir at six months.


 Nelfinavir, the newest protease inhibitor to be approved by the Food and Drug Administration (FDA), showed promising preliminary data when it was combined with AZT and 3TC in treatment-naive populations. Agouron Pharmaceuticals started pediatric trials early in the drug's development, showing that a 20-30 mg/kg dose taken 3 times daily produced roughly the same benefits as 500 to 750 mg in adults. When, where, and how to use nelfinavir in the overall mix of antiviral therapies is still in question. The resistance pattern seems different from the other protease inhibitors and might make it possible to switch to ritonavir or indinavir successfully even after acquiring resistance to nelfinavir. Also, nelfinavir is well-tolerated, has moderate side effects, and can be taken with food. Unfortunately, it may not be as potent as indinavir or ritonavir at currently recommended doses.
